Fresnes, France

Guy Amouret

This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma S.a.. Active years: 2005.


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guy Amouret: Innovator in Pharmaceutical Chemistry

Introduction

Guy Amouret is a notable inventor based in Fresnes, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes in drug preparation. His work has led to the development of a unique patent that showcases his expertise and creativity in the industry.

Latest Patents

Guy Amouret holds a patent for a process titled "Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene." This patent describes a method for preparing 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g] tax-11-ene from a precursor compound through a reaction with a molecular sieve in sulfolane. This innovative process highlights his ability to advance pharmaceutical formulations.

Career Highlights

Guy Amouret is currently associated with Aventis Pharma S.A., where he applies his knowledge and skills to develop new pharmaceutical products. His work at Aventis Pharma has allowed him to contribute to various projects that aim to improve drug efficacy and safety.

Collaborations

One of his notable collaborators is Eric Didier, with whom he has worked on various projects within the pharmaceutical sector. Their partnership has fostered innovation and has led to advancements in their respective fields.

Conclusion

Guy Amouret's contributions to pharmaceutical chemistry through his patent and work at Aventis Pharma S.A. demonstrate his commitment to innovation in the industry. His expertise continues to influence the development of new and effective pharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…